Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balovaptan in Adults With Autism Spectrum Disorder
NCT03504917Phase 3Terminated
- Sponsor
- Roche
- Start
- Aug 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Balovaptan Arm with Placebo Arm (2 arms). Primary endpoint: Vineland Adaptive Behavior Scales Two-domain Composite Score at 24 weeks. Started Aug 2018; status: terminated.
02
Drugs
balovaptan
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03504917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03504917.